Core Insights - The article highlights the successful completion of the GLORY-2 Phase III clinical trial for the world's first GCG/GLP-1 dual receptor agonist, Masitide, developed by Innovent Biologics, targeting severe obesity in China [1][2][3] - The trial demonstrated significant weight loss and improvements in various metabolic parameters among participants with a BMI ≥ 30 kg/m², indicating a potential new treatment option for a population lacking effective pharmacological interventions [1][2] Group 1: Clinical Trial Results - The GLORY-2 study included 462 participants with simple obesity and obesity combined with diabetes, randomized in a 2:1 ratio to receive either Masitide 9mg or a placebo for 60 weeks [2] - Results showed that the Masitide 9mg group achieved significant weight loss compared to the placebo group, along with reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid levels [2] Group 2: Market Potential and Regulatory Plans - Innovent Biologics plans to submit a marketing application for Masitide 9mg to the National Medical Products Administration (NMPA) for adult weight control [3] - The development of Masitide 9mg specifically addresses the weight management needs of patients with a BMI greater than 30 kg/m², particularly those above 32.5 kg/m², who previously relied on surgical interventions for effective weight management [3]

消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港元。 ...

智通财经APP获悉，信达生物(01801)尾盘涨近3%，截至发稿，涨2.62%，报92港元，成交额7.47亿港 元。 消息面上，11月20日，信达生物宣布，玛仕度肽注射液(IBI362)在中国中重度肥胖人群中开展的III期临 床研究(GLORY-2)达成主要终点和所有关键次要终点，信达生物将于近期向监管机构递交玛仕度肽9mg 用于成人体重控制的新药上市申请。 公开资料显示，玛仕度肽是信达生物与礼来制药共同推进的一款胰高血糖素(GCG)/胰高血糖素样 肽-1(GLP-1)双受体激动剂，也是全球首个获批的GCG/GLP-1双受体激动剂。该药已在国内获批两项适 应症，分别用于成人肥胖或超重患者的长期体重控制以及成人2型糖尿病患者的血糖控制。 ...

增持后，JPMorgan Chase & Co.最新持好仓数目为8684.107万股，持好仓比例由4.98%上升至5.06%。 | 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 18/10/2025 - 18/11/2025 | 格隆汇11月18日丨根据联交所最新权益披露资料显示，2025年11月11日，信达生物(01801.HK)获JPMorgan Chase & Co.以每股均价84.7327港元增持好仓 143.88万股，涉资约1.22亿港元。 | Frida Barra | 大 股東/董事/最高行政人員名 作出披露的 買 入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法國 | | --- | --- | --- | --- | --- | --- | | | 版 分享 三 | | | 和人员上面落語 | 有投票樓股期(日/月/ 份權益 | | | | | | | 份自分比 年) | | CS20251114E00461 | JPMorgan Chase & ...

智通财经APP获悉，香港联交所最新资料显示，11月11日，小摩增持信达生物(01801)143.8757万股，每 股作价84.7327港元，总金额约为1.22亿港元。增持后最新持股数目约为8684.11万股，最新持股比例为 5.06%。 ...

Group 1 - JPMorgan increased its stake in Innovent Biologics (01801) by acquiring 1,438,757 shares at a price of HKD 84.7327 per share, totaling approximately HKD 122 million [1] - Following the acquisition, JPMorgan's total shareholding in Innovent Biologics is approximately 86,841,100 shares, representing a stake of 5.06% [1]

Core Viewpoint - Cinda Biologics reported a year-on-year revenue growth of over 40% in Q3, exceeding expectations and indicating strong performance in the biopharmaceutical sector [1] Group 1: Financial Performance - Total product revenue for Cinda Biologics in Q3 surpassed 3.3 billion, with a quarterly growth of 22%, outpacing last year's 15% growth [1] - The company is expected to achieve an annual revenue of approximately 11.5 billion, primarily driven by the sales of Masituzumab and three recently licensed candidate drugs to Takeda [1] Group 2: Future Projections - The firm has raised its total product revenue forecasts for 2025 to 2027 by 1%, 2%, and 1% respectively, projecting revenues of 11.5 billion, 18.3 billion, and 23.3 billion [1] - Adjusted profit forecasts have also been increased to 1.7 billion, 10.3 billion, and 5.6 billion for the same period [1] Group 3: Market Position and Rating - Cinda Biologics is viewed as a leader in biopharmaceuticals for treating challenging chronic and fatal diseases in China [1] - The target price has been raised from 125 HKD to 128 HKD, corresponding to a projected price-to-sales ratio of 10.6 times for 2026, maintaining an "outperform" rating and listing it as a preferred stock in the industry [1]

Core Viewpoint - Jianyin International has raised the target price for Innovent Biologics (01801) by 2.4% from HKD 125 to HKD 128, maintaining a "Outperform" rating, citing the company's robust fundamentals as a preferred stock choice [1] Financial Performance - Innovent Biologics reported total product revenue exceeding RMB 3.3 billion in Q3, representing an annual increase of over 40%, surpassing the previous forecast of a 37% annual growth for total product revenue in 2025 [1] - The revenue forecasts for 2025, 2026, and 2027 have been adjusted upwards by 1%, 2%, and 1% respectively, reaching RMB 11.5 billion, RMB 18.3 billion, and RMB 23.3 billion [1] Strategic Developments - The company has reached an agreement with Takeda Pharmaceutical regarding an authorization deal, expecting to receive a prepayment of USD 1.1 billion by the end of 2026 [1] - As a result of this agreement, the adjusted profit forecasts for 2025, 2026, and 2027 have been increased to RMB 5.6 billion [1]

Core Viewpoint - Jianyin International has raised the target price for Innovent Biologics (01801) by 2.4% from HKD 125 to HKD 128, maintaining a "Outperform" rating, citing the company's robust fundamentals as a preferred stock choice [1] Financial Performance - Innovent Biologics reported total product revenue exceeding RMB 3.3 billion in Q3, representing an annual increase of over 40%, surpassing the previous forecast of a 37% annual growth for total product revenue in 2025 [1] - The revenue forecasts for 2025, 2026, and 2027 have been adjusted upwards by 1%, 2%, and 1% respectively, reaching RMB 11.5 billion, RMB 18.3 billion, and RMB 23.3 billion [1] Strategic Developments - The company has reached an agreement with Takeda Pharmaceutical regarding an authorization deal, expecting to receive an upfront cash reward of USD 1.1 billion by the end of 2026 [1] - As a result of this agreement, the adjusted profit forecasts for 2025, 2026, and 2027 have been increased to RMB 5.6 billion [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 信達生物製藥 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01801 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 F ...